PBAC's latest decision on Lebrikizumab: Recommended with restriction (2024). Considered for Treatment of severe atopic dermatitis in patients aged 12 years or older affecting the whole body or the face and/or hands, who are inadequately controlled on topical therapies.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Patients aged 12 years or older with severe atopic dermatitis (EASI ≥20 and PGA=4 for whole body, or 2 severe EASI symptom subscores or ≥30% surface area for face/hands) inadequately controlled on topical corticosteroids or calcineurin inhibitors.
Therapy area
Dermatology
Line of therapy
Any
Evidence base
Meta-analysis
Primary endpoint
ORR
Comparator
dupilumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.